- Home
- Publications
- Publication Search
- Publication Details
Title
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 14, Issue 6, Pages 561
Publisher
MDPI AG
Online
2021-06-12
DOI
10.3390/ph14060561
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The mineralocorticoid receptor—an emerging player in metabolic syndrome?
- (2021) Moe Thuzar et al. JOURNAL OF HUMAN HYPERTENSION
- Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy
- (2021) Swayam Prakash Srivastava et al. Nature Communications
- Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
- (2020) Daisuke Sueta et al. CURRENT HYPERTENSION REPORTS
- N ‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: an update and translational aspects
- (2020) Keizo Kanasaki Journal of Diabetes Investigation
- Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
- (2020) Nete Tofte et al. Lancet Diabetes & Endocrinology
- Metabolic reprogramming by N‐acetyl‐seryl‐aspartyl‐lysyl‐proline protects against diabetic kidney disease
- (2020) Swayam Prakash Srivastava et al. BRITISH JOURNAL OF PHARMACOLOGY
- Mineralocorticoid Receptor Antagonists in ESKD
- (2020) Adhish Agarwal et al. Clinical Journal of the American Society of Nephrology
- Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
- (2020) Omar Al Dhaybi et al. DIABETES OBESITY & METABOLISM
- Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes
- (2020) Skander Mulder et al. Translational Research
- Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker
- (2020) Kiyoshi Arai et al. HYPERTENSION RESEARCH
- Effect of sodium-glucose Cotransporter 2 inhibitors on cardiovascular and kidney outcomes – Systematic review and meta-analysis of randomized placebo-controlled trials
- (2020) Husam M. Salah et al. AMERICAN HEART JOURNAL
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Novel therapeutic agents for the treatment of diabetic kidney disease
- (2020) Rachel E. Hartman et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
- (2020) Tadakatsu Nakamura et al. Clinical Pharmacology in Drug Development
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
- (2020) Sadayoshi Ito et al. HYPERTENSION RESEARCH
- Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
- (2020) Rajiv Agarwal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
- (2020) Christoph Wanner et al. Clinical Kidney Journal
- Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
- (2019) Abdus Sattar Bhuiyan et al. HYPERTENSION RESEARCH
- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
- (2019) Josef Coresh et al. Lancet Diabetes & Endocrinology
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Esaxerenone: First Global Approval
- (2019) Sean Duggan DRUGS
- Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
- (2019) Sadayoshi Ito et al. JOURNAL OF HUMAN HYPERTENSION
- New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
- (2019) Irene Capelli et al. JOURNAL OF NEPHROLOGY
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Diabetes mellitus Typ 2: Wie schützen wir die Nieren am besten?
- (2019) Susanne Brenner et al. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
- Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
- (2019) Hiroshi Itoh et al. HYPERTENSION RESEARCH
- Rapid Aldosterone-Mediated Signaling in the DCT Increases Activity of the Thiazide-Sensitive NaCl Cotransporter
- (2019) Lei Cheng et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis
- (2019) Chao Zuo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
- (2018) Giuseppe Penno et al. ACTA DIABETOLOGICA
- The Global Epidemiology of Diabetes and Kidney Disease
- (2018) Digsu N. Koye et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects
- (2018) Manabu Kato et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
- (2018) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure
- (2018) Hui Pei et al. MEDICINE
- JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
- (2018) Katherine R Tuttle et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
- (2018) Thomas R. Einarson et al. VALUE IN HEALTH
- Mineralocorticoid Receptor and Cardiovascular Disease
- (2018) Mathieu Buonafine et al. AMERICAN JOURNAL OF HYPERTENSION
- Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology
- (2018) Alessandro Cannavo et al. Oxidative Medicine and Cellular Longevity
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
- (2018) Lei Li et al. HYPERTENSION RESEARCH
- Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials
- (2018) Fan Shunan et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- New pharmacological strategies for protecting kidney function in type 2 diabetes
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
- (2017) Peter Bramlage et al. EUROPEAN JOURNAL OF HEART FAILURE
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology
- (2017) John Funder INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Diabetes with early kidney involvement may shorten life expectancy by 16 years
- (2017) Chi Pang Wen et al. KIDNEY INTERNATIONAL
- The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
- (2017) Christian Bommer et al. Lancet Diabetes & Endocrinology
- Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
- (2016) Jun Yang et al. CURRENT OPINION IN PHARMACOLOGY
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Third-generation Mineralocorticoid Receptor Antagonists
- (2016) Elise P. Gomez-Sanchez JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study: Association with chronic kidney disease
- (2016) Miguel Ángel Salinero-Fort et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Early Aldosterone Blockade in Acute Myocardial Infarction
- (2016) Farzin Beygui et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
- (2016) Makiko Yamada et al. XENOBIOTICA
- Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis
- (2015) Jing Hou et al. CLINICAL THERAPEUTICS
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Mineralocorticoid receptor antagonists, a class beyond spironolactone — Focus on the special pharmacologic properties of eplerenone
- (2015) Petar M. Seferovic et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Excess Mortality among Persons with Type 2 Diabetes
- (2015) Mauro Tancredi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study
- (2014) G. Montalescot et al. EUROPEAN HEART JOURNAL
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial
- (2013) A. Esteghamati et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)
- (2012) David Preiss et al. EUROPEAN JOURNAL OF HEART FAILURE
- Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease
- (2012) Stine E Nielsen et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Spironolactone Rescues Dot1a-Af9-Mediated Repression of Endothelin-1 and Improves Kidney Injury in Streptozotocin-Induced Diabetic Rats
- (2012) Qiaoling Zhou et al. PLoS One
- Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function
- (2011) Matthew D. Taves et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat
- (2011) Bruno S Pessôa et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Aldosterone, mineralocorticoid receptor, and heart failure
- (2011) Smail Messaoudi et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease
- (2011) M. Lian et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Review Article: Eplerenone: An Underused Medication?
- (2010) Mohammad Abuannadi et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
- (2010) Andrew S. Levey et al. KIDNEY INTERNATIONAL
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
- (2009) S. D. Navaneethan et al. Clinical Journal of the American Society of Nephrology
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
- (2009) U. F. Mehdi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats
- (2008) Masateru Taira et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats
- (2008) Y. S. Kang et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started